EyeCRO specializes in preclinical ophthalmic studies to examine the efficacy of novel test agents and therapeutic modalities. Our models are well established and optimized to facilitate generation of reproducible datasets with meaningful endpoints.
With over two decades of experience in vision research, our expert scientists can help you select the right model and experimental design to achieve your research and development goals. We also offer Toxicology/PK studies, and eyedrop formulations in MiDROPS™.
The Global Leader in Preclinical Ophthalmic Research
Microemulsion Drug Ocular Penetration System MiDROPS™
MiDROPS™ was developed to allow for eyedrop formulation of small molecules that are lipophilic. This technology represents a fundamentally new approach for ophthalmic drug delivery using microemulsions which are thermodynamically stable. These self-assembling vehicles can formulate high concentrations of drugs and deliver them in abundant quantities to both the anterior segment and posterior segment. Our broad patents are issued in the US and Worldwide and protect millions of different formulations covered in our library.
Click here to learn more about this innovative platform technology
Models
News & Events
EyeCRO on Twitter
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness https://www.yahoo.com/now/novartis-acquire-gyroscope-therapeutics-adding-070000910.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
Cataract surgery may affect risks of developing dementia, study finds. Here’s why https://news.yahoo.com/cataract-surgery-may-affect-risks-200514857.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @Yahoo
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer https://www.fightingblindness.org/news/sparingvisions-strengthens-leadership-team-311
